Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 1251 results for public health guidance

  1. Our principles

    The principles that guide the development of NICE guidance and standards.

  2. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (NG5)

    This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.

  3. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  4. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  5. VER-01 for treating chronic low back pain [ID6638]

    Awaiting development Reference number: GID-TA11842 Expected publication date: TBC

  6. Ianalumab for treating active Sjogren's syndrome [ID6634]

    Awaiting development Reference number: GID-TA11836 Expected publication date: TBC

  7. Ruxolitinib for treating moderate atopic dermatitis ID6602

    In development Reference number: GID-TA11809 Expected publication date: TBC

  8. Oveporexton for treating type 1 narcolepsy [ID6622]

    In development Reference number: GID-TA11820 Expected publication date: TBC

  9. Ruxolitinib for treating moderate atopic dermatitis ID6602: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 20 May 2026.

  10. Oveporexton for treating type 1 narcolepsy [ID6622]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 21 May 2026.

  11. Consultations

    People can comment on our guidance at specific stages in its development.

  12. Consultations

    People can comment on our guidance at specific stages in its development.

  13. Alcohol use: risk assessment for people with depression or anxiety (IND198)

    This indicator covers the percentage of patients with a new diagnosis of depression or anxiety in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after their diagnosis being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM177

  14. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

  15. Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)

    This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.